General information about company |
|||
|---|---|---|---|
| Scrip Code | 500027 | ||
| NSE Symbol | ATUL | ||
| MSEI Symbol | NOTLISTED | ||
| ISIN | INE100A01010 | ||
| Name of company | ATUL LIMITED | ||
| Type of company | Main Board | ||
| Class of security | Equity | ||
| Date of start of financial year | 01-Apr-2025 | ||
| Date of end of financial year | 31-Mar-2026 | ||
| Date of board meeting when results were approved | 18-Jul-2025 | ||
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 26-Jun-2025 | ||
| Description of presentation currency | INR (in Actuals) | ||
| Reporting Type | Quarterly | ||
| Reporting Quarter | First quarter | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Whether results are audited or unaudited for the quarter ended | Unaudited | ||
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |||
| Segment Reporting | Multi segment | ||
| Description of single segment | |||
| Start date and time of board meeting | 18-Jul-2025 10:00:00 | ||
| End date and time of board meeting | 18-Jul-2025 13:15:00 | ||
| Whether cash flow statement is applicable on company | |||
| Type of cash flow statement | |||
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable | ||
Financial Results Ind-AS |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Consolidated | |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | ||
| 1 | Income | ||
| Revenue from operations | 14780000000 | ||
| Other income | 262400000 | ||
| Total income | 15042400000 | ||
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 7910900000 | |
| (b) | Purchases of stock-in-trade | 195700000 | |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | -520700000 | |
| (d) | Employee benefit expense | 1200200000 | |
| (e) | Finance costs | 45400000 | |
| (f) | Depreciation, depletion and amortisation expense | 820400000 | |
| (f) | Other Expenses | ||
| 1 | Power, fuel and water | 1832200000 | 1832200000 |
| 2 | Other Expenses | 1806700000 | 1806700000 |
| Total other expenses | 3638900000 | ||
| Total expenses | 13290800000 | ||
| 3 | Total profit before exceptional items and tax | 1751600000 | |
| 4 | Exceptional items | 0 | |
| 5 | Total profit before tax | 1751600000 | |
| 6 | Tax expense | ||
| 7 | Current tax | 370600000 | |
| 8 | Deferred tax | 76100000 | |
| 9 | Total tax expenses | 446700000 | |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | |
| 11 | Net Profit Loss for the period from continuing operations | 1304900000 | |
| 12 | Profit (loss) from discontinued operations before tax | 0 | |
| 13 | Tax expense of discontinued operations | 0 | |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 18700000 | |
| 16 | Total profit (loss) for period | 1323600000 | |
| 17 | Other comprehensive income net of taxes | 1765400000 | |
| 18 | Total Comprehensive Income for the period | 3089000000 | |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 1277700000 | ||
| Total profit or loss, attributable to non-controlling interests | 45900000 | ||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 3043100000 | ||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 45900000 | ||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 294400000 | ||
| Face value of equity share capital | 10 | ||
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 43.4 | ||
| Diluted earnings (loss) per share from continuing operations | 43.4 | ||
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | ||
| Diluted earnings (loss) per share from discontinued operations | 0 | ||
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 43.4 | ||
| Diluted earnings (loss) per share from continuing and discontinued operations | 43.4 | ||
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
Disclosure of notes on financial results |
|||
|---|---|---|---|
| Textual Information(1) | 1.tThese results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. ttttttt ntttttttt n2.tThese results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on July 17, 2025 and approved by the Board of Directors in its meeting held on July 18, 2025. The Statutory Auditors have carried out limited review of the consolidated unaudited financial results for the quarter ended on June 30, 2025. Their limited review report does not have any modification.ttttttt ntttttttt n3.tThe Company has reported segment information as per the Ind AS 108, 'Operating Segments', as below:ttttttt ntttttttt ntName of segmentttMain product groupsttttt ntLife Science ChemicalsttActive pharmaceutical ingredients and its intermediates, crop protection chemicalsttttt ntPerformance and Other ChemicalsttAdhesion promoters, bulk chemicals, epoxy resins and hardeners, intermediates, textile dyesttttt ntOthersttAgribiotech, food products, services and othersttttt ntttttttt n4.tOther expenses include ` 24.56 cr for the quarter ended and ` 41.36 cr for the year ended on March 31, 2025 towards application fees, cess, premium, conversion charges, customary penal charges, non-agricultural assessment charges, differential stamp duty, etc, for converting part of the agricultural land to industrial use.ttttttt ntttttttt n5.tThe figures for the quarter ended on March 31, 2025 are the balancing figures between audited figures for the full financial year and the published year-to-date figures up to the third quarter.ttttttt n | ||
Remarks |
|
|---|---|
| Debt equity ratio | |
| Debt service coverage ratio | |
| Interest service coverage ratio | |
Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results |
|||||||
|---|---|---|---|---|---|---|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
| Date of start of reporting period | 01-Apr-2025 | ||||||
| Date of end of reporting period | 30-Jun-2025 | ||||||
| Whether accounts are audited or unaudited | Unaudited | ||||||
| Nature of report standalone or consolidated | Consolidated | ||||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Life Science Chemicals | 4492000000 | 4492000000 | ||||
| 2 | Performance and Other Chemicals | 10669300000 | 10669300000 | ||||
| 3 | Others | 163600000 | 163600000 | ||||
| Total Segment Revenue | 15324900000 | ||||||
| Less: Inter segment revenue | 544900000 | 544900000 | |||||
| Revenue from operations | 14780000000 | ||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Life Science Chemicals | 684100000 | 684100000 | ||||
| 2 | Performance and Other Chemicals | 1000000000 | 1000000000 | ||||
| 3 | Others | 23400000 | 23400000 | ||||
| Total Profit before tax | 1707500000 | ||||||
| i. Finance cost | 45400000 | 45400000 | |||||
| ii. Other Unallocable Expenditure net off Unallocable income | -108200000 | -108200000 | |||||
| Profit before tax | 1770300000 | ||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Life Science Chemicals | 13045300000 | 13045300000 | ||||
| 2 | Performance and Other Chemicals | 37004100000 | 37004100000 | ||||
| 3 | Others | 2290500000 | 2290500000 | ||||
| Total Segment Asset | 52339900000 | 52339900000 | |||||
| Un-allocable Assets | 22694400000 | 22694400000 | |||||
| Net Segment Asset | 75034300000 | 75034300000 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Life Science Chemicals | 3287100000 | 3287100000 | ||||
| 2 | Performance and Other Chemicals | 8061900000 | 8061900000 | ||||
| 3 | Others | 244800000 | 244800000 | ||||
| Total Segment Liabilities | 11593800000 | 11593800000 | |||||
| Un-allocable Liabilities | 3724700000 | 3724700000 | |||||
| Net Segment Liabilities | 15318500000 | 15318500000 | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
Text Block |
|
|---|---|
| Textual Information(2) | 1.tThese results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. ttttttt ntttttttt n2.tThese results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on July 17, 2025 and approved by the Board of Directors in its meeting held on July 18, 2025. The Statutory Auditors have carried out limited review of the consolidated unaudited financial results for the quarter ended on June 30, 2025. Their limited review report does not have any modification.ttttttt ntttttttt n3.tThe Company has reported segment information as per the Ind AS 108, 'Operating Segments', as below:ttttttt ntttttttt ntName of segmentttMain product groupsttttt ntLife Science ChemicalsttActive pharmaceutical ingredients and its intermediates, crop protection chemicalsttttt ntPerformance and Other ChemicalsttAdhesion promoters, bulk chemicals, epoxy resins and hardeners, intermediates, textile dyesttttt ntOthersttAgribiotech, food products, services and othersttttt ntttttttt n4.tOther expenses include ` 24.56 cr for the quarter ended and ` 41.36 cr for the year ended on March 31, 2025 towards application fees, cess, premium, conversion charges, customary penal charges, non-agricultural assessment charges, differential stamp duty, etc, for converting part of the agricultural land to industrial use.ttttttt ntttttttt n5.tThe figures for the quarter ended on March 31, 2025 are the balancing figures between audited figures for the full financial year and the published year-to-date figures up to the third quarter.ttttttt n |
Other Comprehensive Income |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Consolidated | |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Fair value of equity instruments through other comprehensive income | 2024600000 | 2024600000 |
| 2 | Remeasurement gain | (loss) on defined benefit plans | -52400000 | -52400000 |
| Total Amount of items that will not be reclassified to profit and loss | 1972200000 | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 276100000 | |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Effective portion of gain | (loss) on cashflow hedges | -800000 | -800000 |
| 2 | Exchange differences on translation of foreign operations | 75500000 | 75500000 |
| Total Amount of items that will be reclassified to profit and loss | 74700000 | ||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 5400000 | |
| 5 | Total Other comprehensive income | 1765400000 | |